---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031957"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:31:54.294625+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Monopar acquires exclusive worldwide license for ALXN-1840 from Alexion; pays $4M cash + equity

## Summary
- Monopar gets exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson disease; Phase 3 trial met primary endpoint, but Alexion terminated after Phase 2 results.
- Upfront: $4M cash ($1M at signing, $3M in 90 days) and 387,329 shares (9.9% beneficial ownership); anti-dilution up to 705,015 total shares.
- Future milestones up to $94M plus tiered royalties (low to mid-double digit) on net sales; mid-double digit sublicensing income share until sales.
- Cash was ~$6M as of Sep 30, 2024; near-term expenses <$1M for regulatory package; expects substantial doubt about going concern in upcoming 10-Q.
- ALXN-1840 has Orphan Drug Designation in US and EU; Monopar plans to initiate FDA discussions; regulatory path uncertain.

## SEC filing metadata
- accession: 0001437749-24-031957
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924031957/0001437749-24-031957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924031957/mnpr20241021_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031957
- JSON: https://secwatch.observer/filing/0001437749-24-031957.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.